BioSpace News Archive

AccuraDX has launched the KAS-Direct™ ssDNA Labeling and Enrichment Kit to provide researchers with a simple and robust way to directly label and read out transcription activity genome-wide to identify cell states in different biological processes.

Novamind Inc., a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Assure Holdings Corp. announced that management will participate in the Lake Street 5th Annual Best Ideas Growth (BIG5) Conference on Wednesday, September 15th, 2021.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research on its first-in-class antibody-drug conjugate (ADC) Trodelvy® (sacituzumab govitecan-hziy) at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16–21, 2021.

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and their functions in the body can effectively be used in clinical care.

Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has been granted priority review of the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk).

AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned experts from a top-tier hospital in China, jointly published an article entitled “Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis” in well-known journal, npj Breast Cancer.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today successful treatment of a United States Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE).

Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, announced today the signing of a definitive partnership agreement with Roche Diagnostics International Ltd.